MCID: URN010
MIFTS: 55

Urinary Tract Obstruction malady

Categories: Nephrological diseases

Aliases & Classifications for Urinary Tract Obstruction

Aliases & Descriptions for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 14 69
Obstructive Uropathy 12 52
Urinary Obstruction 12
Urologic Diseases 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5200
ICD10 33 N13.9
ICD9CM 35 599.6 599.60
NCIt 47 C3675 C79805
UMLS 69 C0178879

Summaries for Urinary Tract Obstruction

MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to renal tubular acidosis and split-hand with obstructive uropathy, spina bifida, and diaphragmatic defects, and has symptoms including dysuria, polyuria and pain in urethra. An important gene associated with Urinary Tract Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Fentanyl and Levobupivacaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and prostate, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 71 Urinary tract obstruction is a urologic disease consisting of a decrease in the free passage of urine... more...

Related Diseases for Urinary Tract Obstruction

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Related Disease Score Top Affiliating Genes
1 renal tubular acidosis 29.2 CCL2 CTGF SMAD3 TGFB1
2 split-hand with obstructive uropathy, spina bifida, and diaphragmatic defects 12.1
3 kashani strom utley syndrome 11.2
4 cystinuria 11.1
5 renal hypodysplasia/aplasia 2 11.1
6 renal hypodysplasia/aplasia 1 11.1
7 pelvic lipomatosis 11.1
8 split hand urinary anomalies spina bifida 11.0
9 gliosarcoma 10.2 ALB B2M NAGLU
10 congenital nystagmus 10.2 ALB B2M REN
11 aphthous stomatitis 10.2 ALB CTGF TGFB1
12 schizotypal personality disorder 10.2 ALB REN UMOD
13 vibratory urticaria 10.2 SMAD2 SMAD3 TGFB1
14 systolic heart failure 10.2 B2M NAGLU TGFB1 UMOD
15 speech and communication disorders 10.2 SMAD2 SMAD3 TGFB1
16 idiopathic juvenile osteoporosis 10.2 ALB B2M NAGLU UMOD
17 gilles de la tourette syndrome 10.2 ALB B2M
18 mixed germ cell-sex cord neoplasm 10.2 ALB NAGLU REN TGFB1
19 high-grade dysplasia in patients with barrett esophagus 10.1 NAGLU REN SLPI
20 acute lymphoblastic leukemia, childhood 10.1 ALB B2M REN
21 myopia 10.1 ALB AQP2 REN
22 esophageal neuroendocrine tumor 10.1 CDH1 PTGS2 TGFB1
23 upper respiratory tract disease 10.1 CTGF SMAD2 TGFB1
24 agammaglobulinemia 6 10.1 ALB CTGF NAGLU TGFB1
25 paranasal sinus sarcoma 10.1 ALB GGT1 REN
26 noninfectious dermatoses of eyelid 10.1 ALB GGT1 TGFB1
27 uterine corpus dissecting leiomyoma 10.1 CDH1 HBEGF UMOD
28 hereditary spastic paraplegia 10.1 ALB GGT1 PIK3CA TGFB1
29 chronic myocardial ischemia 10.1 ALB B2M REN UMOD
30 hereditary night blindness 10.1 CTGF SMAD3 TGFB1
31 rhinitis 10.1 KLK3 SMAD2 SMAD3
32 hemiplegia 10.1 ALB CCL2 NAGLU
33 demyelinating polyneuropathy 10.1 AQP2 PTGS2 TGFB1
34 patent foramen ovale 10.1 ALB CTGF TGFB1
35 allergic bronchopulmonary aspergillosis 10.1 ALB CCL2 KLK3
36 choroiditis 10.1 ALB CCL2 NAGLU
37 neovascular glaucoma 10.0 CCL2 HBEGF PTGS2 UMOD
38 urethritis 10.0
39 henoch-schoenlein purpura 10.0 ALB AQP2 B2M NAGLU TGFB1
40 lung giant cell carcinoma 10.0 ALB B2M NAGLU REN UMOD
41 sclerosing adenosis of breast 10.0 ALB B2M CCL2 TGFB1
42 hypogonadotropic hypogonadism 20 with or without anosmia 10.0 CDH1 PIK3CA PTGS2 TGFB1
43 familial nephrotic syndrome 10.0 ALB TGFB1 UMOD
44 proctitis 10.0 ALB CDH1 PIK3CA PTGS2 TGFB1
45 heart valve disease 10.0 ALB B2M CCL2 TGFB1
46 hypertrichosis of eyelid 10.0 CCL2 CTGF TGFB1
47 lubani-al saleh-teebi syndrome 10.0 SMAD3 SMAD7 TGFB1
48 albinism, oculocutaneous, type ia 10.0 CCL2 CTGF TGFB1
49 ladd syndrome 9.9 CDH1 KLK3 PIK3CA PTGS2
50 albright's hereditary osteodystrophy 9.9 SMAD2 SMAD3 SMAD7

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hydronephrosis
Kidney Disease Nephrolithiasis, Type I
Paralytic Ileus Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Prostatitis Protein-Energy Malnutrition
Ureterolithiasis Urethral Stricture
Urinary Bladder Cancer

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction

Symptoms & Phenotypes for Urinary Tract Obstruction

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, pain in urethra, renal colic, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, uti symptoms, bladder discomfort, renal pain, other and unspecified genitourinary symptoms, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 AQP2 B2M CDH1 CTGF GGT1 HBEGF
2 homeostasis/metabolism MP:0005376 10.41 ALB AQP2 B2M CDH1 CTGF GGT1
3 behavior/neurological MP:0005386 10.39 REN SLC5A6 SMAD2 SMAD3 SMAD7 TGFB1
4 cardiovascular system MP:0005385 10.38 B2M CDH1 CTGF HBEGF NAGLU PIK3CA
5 cellular MP:0005384 10.34 PIK3CA PTGS2 SMAD2 SMAD3 SMAD7 TGFB1
6 immune system MP:0005387 10.33 REN SLC5A6 SLPI SMAD2 SMAD3 SMAD7
7 mortality/aging MP:0010768 10.3 CTGF GGT1 HBEGF NAGLU PIK3CA PTGS2
8 endocrine/exocrine gland MP:0005379 10.26 ALB B2M CDH1 GGT1 PIK3CA PTGS2
9 digestive/alimentary MP:0005381 10.25 ALB B2M CDH1 CTGF PTGS2 SLC5A6
10 integument MP:0010771 10.25 PTGS2 SMAD2 SMAD3 SMAD7 TGFB1 AQP2
11 hematopoietic system MP:0005397 10.24 AQP2 B2M GGT1 NAGLU PTGS2 REN
12 embryo MP:0005380 10.14 PIK3CA PTGS2 SMAD2 SMAD3 SMAD7 TGFB1
13 liver/biliary system MP:0005370 10.01 PTGS2 SLC5A6 SMAD2 SMAD3 TGFB1 ALB
14 renal/urinary system MP:0005367 9.96 GGT1 NAGLU PTGS2 REN SLC5A6 SMAD3
15 neoplasm MP:0002006 9.92 ALB B2M CDH1 PIK3CA PTGS2 SMAD2
16 reproductive system MP:0005389 9.9 AQP2 B2M CDH1 GGT1 PIK3CA PTGS2
17 skeleton MP:0005390 9.7 CTGF GGT1 HBEGF NAGLU PIK3CA PTGS2
18 vision/eye MP:0005391 9.23 CTGF GGT1 NAGLU PIK3CA PTGS2 SMAD2

Drugs & Therapeutics for Urinary Tract Obstruction

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
2
Levobupivacaine Approved Phase 4 27262-47-1 92253
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Doxazosin Approved Phase 4 74191-85-8 3157
6
Alfuzosin Approved, Investigational Phase 4,Phase 3 81403-80-7 2092
7
Dutasteride Approved, Investigational Phase 4,Phase 3 164656-23-9 152945 6918296
8
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10
Sulfamethoxazole Approved Phase 4 723-46-6 5329
11
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13
Silodosin Approved Phase 4 160970-54-7
14
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106133-20-4 129211
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
18
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
19
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
20
Norgestimate Approved Phase 4 35189-28-7 6540478
21
Mirabegron Approved Phase 4,Phase 2 223673-61-8
22
Acetaminophen Approved Phase 4 103-90-2 1983
23
Baclofen Approved Phase 4 1134-47-0 2284
24
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
27 Adjuvants, Anesthesia Phase 4
28 Analgesics Phase 4,Phase 3
29 Analgesics, Opioid Phase 4
30 Anesthetics Phase 4,Phase 2,Phase 1
31 Anesthetics, General Phase 4
32 Anesthetics, Intravenous Phase 4
33 Anesthetics, Local Phase 4,Phase 2,Phase 1
34 Anti-Anxiety Agents Phase 4
35 Anti-Arrhythmia Agents Phase 4,Phase 2
36 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
37 Diuretics, Potassium Sparing Phase 4,Phase 2
38 GABA Agents Phase 4
39 GABA Modulators Phase 4
40 Hypnotics and Sedatives Phase 4
41 Narcotics Phase 4
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Psychotropic Drugs Phase 4
45 Sodium Channel Blockers Phase 4,Phase 2
46 Tranquilizing Agents Phase 4
47 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
49 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 122)
id Name Status NCT ID Phase
1 Quadratus Lumborum Block for Percutaneous Nephrostomy Unknown status NCT02121951 Phase 4
2 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4
3 Functional MR Urography Completed NCT00301470 Phase 4
4 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Completed NCT00696761 Phase 4
5 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Completed NCT01661621 Phase 4
6 Evaluation of Symptom-specific Goal Achievement Completed NCT00836823 Phase 4
7 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4
8 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
9 Analgesic Efficacy of Ultrasound Guided Quadratus Lumborum Block During ESWL Completed NCT03080363 Phase 4
10 Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation Completed NCT01820897 Phase 4
11 Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Bladder Function Completed NCT02414373 Phase 4
12 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4
13 Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction Completed NCT00147654 Phase 4
14 BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia Completed NCT01533038 Phase 4
15 Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy Completed NCT00934999 Phase 4
16 Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD Completed NCT01710488 Phase 4
17 Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia Completed NCT00665327 Phase 4
18 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Recruiting NCT02095665 Phase 4
19 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate Recruiting NCT02749604 Phase 4
20 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4
21 Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Terminated NCT01003249 Phase 4
22 Tetra-NIRS Clinical Study Terminated NCT00871975 Phase 4
23 Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea Withdrawn NCT01861145 Phase 4
24 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3
25 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3
26 Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic Unknown status NCT01742689 Phase 3
27 Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction Unknown status NCT01220726 Phase 3
28 This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo. Unknown status NCT00479596 Phase 2, Phase 3
29 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3
30 Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) Completed NCT01846793 Phase 3
31 Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Completed NCT01438775 Phase 3
32 Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence Recruiting NCT02112591 Phase 3
33 Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients Recruiting NCT02729116 Phase 2, Phase 3
34 The Safety and Effectiveness of UroLift: LIFT Pivotal Study Active, not recruiting NCT01294150 Phase 3
35 Low-level Light Therapy for Overactive Bladder and Urinary Incontinence Not yet recruiting NCT02980328 Phase 3
36 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3
37 Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease Terminated NCT00562692 Phase 3
38 Use of Alfuzosin in Stone Treatment With ESWL Withdrawn NCT00388271 Phase 3
39 Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2
40 Transurethral Myoblast Injection for Urinary Incontinence in Children With Bladder Exstrophy Unknown status NCT02075216 Phase 1, Phase 2
41 Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction Completed NCT00507455 Phase 2
42 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed NCT00410514 Phase 2
43 Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms Completed NCT02244281 Phase 2
44 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
45 Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms Completed NCT00408954 Phase 2
46 Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity Completed NCT00441428 Phase 2
47 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract Completed NCT03159143 Phase 2
48 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
49 Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia Recruiting NCT02639442 Phase 1, Phase 2
50 Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Recruiting NCT02537847 Phase 2

Search NIH Clinical Center for Urinary Tract Obstruction

Genetic Tests for Urinary Tract Obstruction

Anatomical Context for Urinary Tract Obstruction

MalaCards organs/tissues related to Urinary Tract Obstruction:

39
Kidney, Testes, Prostate, Lung, Smooth Muscle, Neutrophil, B Cells

Publications for Urinary Tract Obstruction

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 335)
id Title Authors Year
1
Fetal Serum I^2-Microglobulin and Postnatal Renal Function in Lower Urinary Tract Obstruction Treated with Vesicoamniotic Shunt. ( 27603215 )
2016
2
Urinary tract obstruction: NLRP3 inhibition prevents BOO. ( 26754189 )
2016
3
Vesico-amniotic shunting for lower urinary tract obstruction in a fetus with VACTERL association. ( 27061706 )
2016
4
Anterior Urethral Valve: A Rare But an Important Cause of Infravesical Urinary Tract Obstruction. ( 27231492 )
2016
5
Analysis of Preoperative Urinary Tract Obstruction in Patients with Scoliosis. ( 27507671 )
2016
6
Effectiveness of vesico-amniotic shunt in fetuses with congenital lower urinary tract obstruction: An updated systematic review and meta-analysis. ( 27270578 )
2016
7
Urinary tract obstruction: Stem cells hinder stricture formation. ( 27349369 )
2016
8
Lower urinary tract obstruction in male children - a report of three cases. ( 27622420 )
2016
9
Factors associated with fetal shunt dislodgement in lower urinary tract obstruction. ( 27247093 )
2016
10
EP21.11: Prediction of shunt dislodgement in fetuses with lower urinary tract obstruction. ( 27646514 )
2016
11
Sequential fetal serum I^2-microglobulin to predict postnatal renal function in bilateral or low urinary tract obstruction. ( 27197901 )
2016
12
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2016
13
Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction. ( 26739350 )
2016
14
Are ultrasound renal aspects associated with urinary biochemistry in fetuses with lower urinary tract obstruction? ( 27862070 )
2016
15
Re: Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. R. Ruano, N. Sananes, H. Sangi-Haghpeykar, S. Hernandez-Ruano, R. Moog, F. Becmeur, A. Zaloszyc, A. M. Giron, B. Morin and R. Favre. Ultrasound Obstet Gynecol 2015; 45: 452-458. ( 25833370 )
2015
16
Defining and predicting 'intrauterine fetal renal failure' in congenital lower urinary tract obstruction. ( 26525197 )
2015
17
Outcome in fetal lower urinary tract obstruction: a prospective registry. ( 25689128 )
2015
18
Fetal Lower Urinary Tract Obstruction - A proposal of Standardized Multidisciplinary Prenatal Management based on Disease Severity. ( 26690832 )
2015
19
Postobstructive diuresis in cats with naturally occurring lower urinary tract obstruction: incidence, severity and association with laboratory parameters on admission. ( 26179575 )
2015
20
Congenital urinary tract obstruction: the long view. ( 26088076 )
2015
21
Current applications of in utero intervention for lower urinary tract obstruction. ( 26441047 )
2015
22
Fetal Lower Urinary Tract Obstruction (LUTO): a practical review for providers. ( 27057343 )
2015
23
Pathological feature and immunoprofile of cystitis glandularis accompanied with upper urinary tract obstruction. ( 25136635 )
2014
24
Palliative management of malignant upper urinary tract obstruction. ( 26052193 )
2014
25
Fetal urine biochemistry at 13-23 weeks in low urinary tract obstruction: criteria for in utero treatment. ( 25412852 )
2014
26
Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesico-amniotic shunting. ( 25157756 )
2014
27
Lower urinary tract obstruction in the fetus and neonate. ( 25155733 )
2014
28
Erdheim-Chester disease: an uncommon cause of upper urinary tract obstruction. ( 24088590 )
2013
29
Prenatal cytogenetic diagnosis from fetal urine in lower urinary tract obstruction. ( 23751043 )
2013
30
Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. ( 23953766 )
2013
31
Clinical character of cystitis glandularis accompanied with upper urinary tract obstruction. ( 24282462 )
2013
32
The experience of pregnant women with a diagnosis of fetal lower urinary tract obstruction (LUTO). ( 24290423 )
2013
33
Outcomes of fetuses with lower urinary tract obstruction treated with vesicoamniotic shunt: a single-institution experience. ( 23701767 )
2013
34
Fetal lower urinary tract obstruction and its management. ( 23138754 )
2013
35
Urinary tract obstruction in the mouse: the kinetics of distal nephron injury. ( 23917879 )
2013
36
PI3K mediates stretch-induced COX-2 expression during urinary tract obstruction. ( 22998445 )
2013
37
Monosodium glutamate (MSG) consumption is associated with urolithiasis and urinary tract obstruction in rats. ( 24086562 )
2013
38
The Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO) study and randomised controlled trial: evaluation of the effectiveness, cost-effectiveness and acceptability of percutaneous vesicoamniotic shunting for lower urinary tract obstruction. ( 24331029 )
2013
39
Postmortem high-resolution fetal magnetic resonance imaging in three cases of lower urinary tract obstruction. ( 23752166 )
2013
40
Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis. ( 23228281 )
2013
41
Effects of tolterodine and trospium chloride on renal damage induced by partial upper urinary tract obstruction. ( 23453648 )
2013
42
A rare case of paediatric pelvic ring injury with lower urinary tract obstruction secondary to a combat blast mechanism. ( 23746855 )
2013
43
Microtomographic analysis of lower urinary tract obstruction. ( 23977847 )
2013
44
Evaluation of the Cost Effectiveness of Vesico-Amniotic Shunting in the Management of Congenital Lower Urinary Tract Obstruction (Based on Data from the PLUTO Trial). ( 24376546 )
2013
45
Laparoscopic ureterocalicostomy for complicated upper urinary tract obstruction: mid-term follow-up. ( 24217801 )
2013
46
Urinary tract obstruction. ( 23502199 )
2012
47
Robotic-assisted laparoscopic vesiculectomy for lower urinary tract obstruction by a large seminal vesicle cyst. ( 22613183 )
2012
48
Outcome of prenatally detected bilateral higher urinary tract obstruction or megacystis: sex-related study on a series of 709 cases. ( 22544566 )
2012
49
Migrated embolization coil: A rare cause of urinary tract obstruction. ( 23450085 )
2012
50
Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. ( 21720861 )
2012

Variations for Urinary Tract Obstruction

Expression for Urinary Tract Obstruction

Search GEO for disease gene expression data for Urinary Tract Obstruction.

Pathways for Urinary Tract Obstruction

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 37)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 CCL2 CDH1 CTGF PIK3CA SMAD2 SMAD3
2
Show member pathways
13 CCL2 CTGF HBEGF PTGS2 REN TGFB1
3 12.46 CDH1 KLK3 PIK3CA PTGS2 SMAD2 SMAD3
4
Show member pathways
12.45 CDH1 HBEGF PIK3CA SMAD2 SMAD3 TGFB1
5 12.38 PIK3CA SMAD2 SMAD3 TGFB1
6 12.32 CDH1 SMAD2 SMAD3 TGFB1
7
Show member pathways
12.3 CDH1 PIK3CA SMAD2 SMAD3 TGFB1
8
Show member pathways
12.28 ALB CCL2 GGT1 PTGS2
9 12.25 HBEGF PIK3CA SMAD2 TGFB1
10
Show member pathways
12.24 SMAD2 SMAD3 SMAD7 TGFB1
11 12.09 GGT1 HBEGF SLC5A6 TGFB1
12 12.07 CDH1 PTGS2 SMAD2 SMAD3 TGFB1
13
Show member pathways
12.06 PIK3CA SMAD2 SMAD3 TGFB1
14 12.05 CDH1 CTGF SMAD2 SMAD3
15
Show member pathways
12.05 PIK3CA SMAD2 SMAD3 TGFB1
16 12.02 SMAD2 SMAD3 SMAD7 TGFB1
17
Show member pathways
11.93 HBEGF KLK3 PIK3CA SMAD3 TGFB1
18 11.88 SMAD2 SMAD3 SMAD7 TGFB1
19
Show member pathways
11.82 SMAD2 SMAD3 TGFB1
20 11.82 CDH1 CTGF SMAD2 SMAD3 SMAD7 TGFB1
21 11.78 CCL2 PTGS2 REN TGFB1
22 11.75 SMAD2 SMAD3 SMAD7 TGFB1
23 11.72 SMAD2 SMAD3 SMAD7
24
Show member pathways
11.72 SMAD2 SMAD3 TGFB1
25 11.68 CDH1 SMAD2 SMAD3
26 11.67 SMAD2 SMAD3 SMAD7 TGFB1
27 11.65 CCL2 PIK3CA SMAD2 SMAD3 TGFB1
28
Show member pathways
11.64 SMAD2 SMAD3 SMAD7 TGFB1
29 11.53 CCL2 CTGF SMAD7 TGFB1
30 11.51 PTGS2 SMAD3 TGFB1
31 11.47 SMAD2 SMAD3 SMAD7 TGFB1
32
Show member pathways
11.44 SMAD2 SMAD3 TGFB1
33 11.24 SMAD2 SMAD3 TGFB1
34 11.14 CTGF SMAD2 SMAD3
35 11.13 CCL2 HBEGF PIK3CA
36 10.73 CTGF SMAD2 SMAD3 SMAD7 TGFB1
37 10.51 CDH1 SMAD2 SMAD3 TGFB1

GO Terms for Urinary Tract Obstruction

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.73 ALB KLK3 PTGS2 SMAD2 SMAD3 SMAD7
2 extracellular region GO:0005576 9.7 ALB B2M CCL2 CDH1 CTGF HBEGF
3 catenin complex GO:0016342 9.4 CDH1 SMAD7
4 SMAD protein complex GO:0071141 9.37 SMAD2 SMAD3
5 extracellular space GO:0005615 9.32 ALB B2M CCL2 CTGF GGT1 HBEGF
6 SMAD2-SMAD3 protein complex GO:0071144 9.16 SMAD2 SMAD3
7 plasma membrane GO:0005886 10.13 AQP2 B2M CDH1 CTGF GGT1 HBEGF

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 38)
id Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.96 CCL2 CTGF PIK3CA PTGS2
2 response to lipopolysaccharide GO:0032496 9.91 CCL2 PTGS2 REN SLPI
3 aging GO:0007568 9.88 CCL2 CTGF PTGS2 TGFB1
4 response to drug GO:0042493 9.85 B2M CCL2 CDH1 PTGS2 REN TGFB1
5 response to wounding GO:0009611 9.83 CCL2 CTGF TGFB1
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 PIK3CA PTGS2 TGFB1
7 response to glucose GO:0009749 9.82 CTGF SMAD2 TGFB1
8 SMAD protein signal transduction GO:0060395 9.78 SMAD2 SMAD3 TGFB1
9 cellular response to transforming growth factor beta stimulus GO:0071560 9.77 SMAD3 SMAD7 TGFB1
10 epidermal growth factor receptor signaling pathway GO:0007173 9.77 HBEGF PIK3CA TGFB1
11 response to organic substance GO:0010033 9.73 CDH1 PTGS2 REN TGFB1
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.71 SMAD2 SMAD3 TGFB1
13 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.71 SMAD2 SMAD3 SMAD7 TGFB1
14 protein kinase B signaling GO:0043491 9.7 CCL2 PIK3CA TGFB1
15 endoderm development GO:0007492 9.69 SMAD2 SMAD3 TGFB1
16 negative regulation of cell-cell adhesion GO:0022408 9.68 CDH1 TGFB1
17 cellular response to ATP GO:0071318 9.67 CCL2 PTGS2
18 pathway-restricted SMAD protein phosphorylation GO:0060389 9.67 SMAD7 TGFB1
19 lens fiber cell differentiation GO:0070306 9.67 SMAD3 TGFB1
20 positive regulation of cell-cell adhesion GO:0022409 9.66 CCL2 SMAD7
21 embryonic foregut morphogenesis GO:0048617 9.64 SMAD2 SMAD3
22 response to cholesterol GO:0070723 9.64 SMAD2 TGFB1
23 primary miRNA processing GO:0031053 9.63 SMAD2 SMAD3
24 pericardium development GO:0060039 9.63 SMAD2 SMAD3
25 positive regulation of collagen biosynthetic process GO:0032967 9.63 CCL2 CTGF TGFB1
26 response to laminar fluid shear stress GO:0034616 9.62 SMAD7 TGFB1
27 ureteric bud development GO:0001657 9.62 SMAD2 SMAD3 SMAD7 TGFB1
28 nodal signaling pathway GO:0038092 9.58 SMAD2 SMAD3
29 common-partner SMAD protein phosphorylation GO:0007182 9.57 SMAD2 TGFB1
30 regulation of striated muscle tissue development GO:0016202 9.56 SMAD3 TGFB1
31 positive regulation of extracellular matrix assembly GO:1901203 9.55 SMAD3 TGFB1
32 transforming growth factor beta receptor signaling pathway GO:0007179 9.55 CCL2 SMAD2 SMAD3 SMAD7 TGFB1
33 paraxial mesoderm morphogenesis GO:0048340 9.49 SMAD2 SMAD3
34 evasion or tolerance of host defenses by virus GO:0019049 9.48 SMAD3 TGFB1
35 SMAD protein complex assembly GO:0007183 9.43 SMAD2 SMAD3 TGFB1
36 regulation of binding GO:0051098 9.13 SMAD2 SMAD3 TGFB1
37 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 8.92 SMAD2 SMAD3 SMAD7 TGFB1
38 negative regulation of cell proliferation GO:0008285 10.02 PTGS2 SMAD2 SMAD3 TGFB1 UMOD

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-catenin binding GO:0008013 9.58 CDH1 SMAD3 SMAD7
2 co-SMAD binding GO:0070410 9.43 SMAD2 SMAD3
3 glycoprotein binding GO:0001948 9.43 B2M CDH1 TGFB1
4 I-SMAD binding GO:0070411 9.37 SMAD2 SMAD7
5 primary miRNA binding GO:0070878 9.32 SMAD2 SMAD3
6 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.16 SMAD2 SMAD3
7 transforming growth factor beta receptor binding GO:0005160 9.13 SMAD2 SMAD3 TGFB1
8 type I transforming growth factor beta receptor binding GO:0034713 8.8 SMAD2 SMAD7 TGFB1

Sources for Urinary Tract Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....